A Phase I/IIa, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sodium Stibogluconate in Combination With Interferon Alpha-2b for Patients With Advanced Malignancies.

Trial Profile

A Phase I/IIa, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sodium Stibogluconate in Combination With Interferon Alpha-2b for Patients With Advanced Malignancies.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 22 Nov 2011

At a glance

  • Drugs Interferon alpha-2b; Sodium stibogluconate
  • Indications Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 21 Nov 2011 Phase II part of trial discontinued before enrollment commenced.
    • 21 Nov 2011 Phase II part of trial discontinued before enrollment commenced.
    • 19 Feb 2010 Status of phase I part of trial changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top